⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924687 | 1.00 | — | — | |
| SCHEMBL18924672 | 1.00 | — | — | |
| SCHEMBL18724693 | 0.86 | — | — | |
| SCHEMBL1911382 | 0.86 | — | — | |
| SCHEMBL18724761 | 0.86 | — | — | |
| SCHEMBL361400 | 0.85 | — | — | |
| SCHEMBL16609932 | 0.79 | — | — | |
| SCHEMBL27936411 | 0.77 | — | — | |
| SCHEMBL12802126 | 0.76 | MAPK1 (0.33) | — | |
| SCHEMBL10866589 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143052-A | Preparation process of tetrahydrofuran-3-methylamine | 绍兴贝斯美化工股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | claimed |
| CN-114727983-A | Xanthine CB1 inhibitors | 金翅雀生物公司 | 2022-07-08 | — | — | CN | claimed |
| CN-111303083-A | Synthetic method of 3-aminomethyl tetrahydrofuran | 安徽中羰碳一工业技术有限责任公司 | 2020-06-19 | — | — | CN | claimed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | claimed |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | claimed |
| CN-109890826-A | A kind of efficient IDO/TDO double inhibitors containing azacyclo- helical structure | 中国科学院上海有机化学研究所 | 2019-06-14 | — | — | CN | claimed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | claimed |
| CN-115803322-B | SARS-COV-2 inhibitors with covalent modifications for treatment of coronavirus infection | 英矽智能科技知识产权有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| CN-117143052-A | Preparation process of tetrahydrofuran-3-methylamine | 绍兴贝斯美化工股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117143052-A | Preparation process of tetrahydrofuran-3-methylamine | 绍兴贝斯美化工股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-08 | — | — | US | disclosed |
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-08 | — | — | US | disclosed |
| EP-1853586-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006087543-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | disclosed |